Lilly Bounces Into 'Sell in May' Territory as Pricing Pressures Loom

"Lilly closed Monday at $966.99, up 2.9% over the past month and 31.6% over the past year, yet still down 10.0% year to date. That mismatch between a hot tape and a red YTD line is exactly what the "Sell in May" crowd hunts for. The catalyst was a blowout Q1 report. Revenue hit $19.799 billion, growing 55.55% year over year, with non-GAAP EPS of $8.55 beating consensus by 25.88%."

"Realized prices fell 13% even as volume jumped 65%, a margin headwind that worsens with the Mounjaro NRDL listing in China and Zepbound cash-pay cuts. Drug pricing rhetoric tends to flare through summer political cycles. The franchise is concentrated, valuation is rich at a 34 P/E, and the Lilly Endowment disposed of 15,828 shares on May 6 near $995. These factors create a trim case despite strong demand."

"CEO David Ricks described the pipeline this way: "Foundayo will meaningfully expand the number of people who can benefit from GLP-1s." Orforglipron beat oral semaglutide head to head in The Lancet, retatrutide is advancing, and four acquisitions deepen the bench. Four directors have systematically added shares at $1,036.05, $989.12, and $919.90. The analyst consensus target stands at $1,209.14 with 24"

"Sentiment spiked to 85 (very bullish) on April 30, then faded to neutral within 72 hours, a classic relief-bounce signature. The stock’s rebound off post-earnings lows created a tactical setup where near-term strength contrasts with a still-negative year-to-date performance. This pattern is often associated with seasonal traders looking for a short-term trim rather than a full exit."

Lilly shares rose sharply after a strong Q1 report, with revenue growth of 55.55% year over year and non-GAAP EPS of $8.55 beating expectations. Mounjaro and Zepbound delivered major revenue gains, and full-year revenue guidance was raised to $82.0 billion to $85.0 billion. Despite the rally, the stock remained down 10.0% year to date, creating an asymmetric profile that aligns with “Sell in May” tactics. Sentiment surged then faded quickly, consistent with a relief-bounce pattern. Margin pressure emerged as realized prices fell 13% while volume rose 65%, with additional headwinds from China NRDL listing and cash-pay cuts. Offsetting factors include pipeline expansion, clinical progress, acquisitions, and insider and director buying, alongside a high analyst consensus target.

Read at 24/7 Wall St.